Lu sur https://www.ncbi.nlm.nih.gov/pubmed/28549776
Traduction disponible directement en cliquant en bas à droite de ce message sur notre forum
Methylome and transcriptome profiling in Myasthenia Gravis monozygotic twins.
Mamrut S1, Avidan N1, Truffault F2, Staun-Ram E1, Sharshar T3, Eymard B4, Frenkian M2, Pitha J5, de Baets M6, Servais L7, Berrih-Aknin S2, Miller A8.
J Autoimmun. 2017 May 23. pii: S0896-8411(17)30130-0. doi: 10.1016/j.jaut.2017.05.005.
To identify novel genetic and epigenetic factors associated with Myasthenia gravis (MG) using an identical twins experimental study design.
The transcriptome and methylome of peripheral monocytes were compared between monozygotic (MZ) twins discordant and concordant for MG, as well as with MG singletons and healthy controls, all females. Sets of differentially expressed genes and differentially methylated CpGs were validated using RT-PCR for expression and target bisulfite sequencing for methylation on additional samples.
>100 differentially expressed genes and ∼1800 differentially methylated CpGs were detected in peripheral monocytes between MG patients and controls. Several transcripts associated with immune homeostasis and inflammation resolution were reduced in MG patients. Only a relatively few genes differed between the discordant healthy and MG co-twins, and both their expression and methylation profiles demonstrated very high similarity.
This is the first study to characterize the DNA methylation profile in MG, and the expression profile of immune cells in MZ twins with MG. Results suggest that numerous small changes in gene expression or methylation might together contribute to disease. Impaired monocyte function in MG and decreased expression of genes associated with inflammation resolution could contribute to the chronicity of the disease. Findings may serve as potential new predictive biomarkers for disease and disease activity, as well as potential future targets for therapy development. The high similarity between the healthy and the MG discordant twins, suggests that a molecular signature might precede a clinical phenotype, and that genetic predisposition may have a stronger contribution to disease than previously assumed.